How does yervoy enhance the body's anti tumor defenses?

How does Yervoy activate immune cells?

Yervoy contains the active ingredient ipilimumab. It belongs to a class of medicines called CTLA-4 inhibitors. The drug attaches to CTLA-4, a protein on the surface of T cells. CTLA-4 normally acts as a brake on the immune system. By binding to it, Yervoy releases that brake and allows T cells to attack tumor cells more strongly [1].

What happens when CTLA-4 is blocked?

Blocking CTLA-4 increases T-cell proliferation and activity. This leads to a broader and stronger immune attack against cancer cells. The effect occurs mainly in lymph nodes and at the site of the tumor [2].

Does Yervoy work alone or with other drugs?

Yervoy is often used in combination with Opdivo (nivolumab), a PD-1 inhibitor. The combination widens the immune response because it targets two different checkpoints at the same time. In melanoma and renal cell carcinoma, the dual blockade produces higher response rates than Yervoy alone [3].

Can biosimilars enter before patent expiry?

Yervoy's composition-of-matter patent expires in 2025. A secondary patent covering formulations expires in 2033. Biosimilars are not yet approved in the U.S. or Europe, but several companies have biosimilar ipilimumab in development [4].

When does patent expire?

The earliest patent expiry for Yervoy is 2025. Secondary patents and regulatory exclusivities may still delay generic or biosimilar entry until 2033 or later. Check DrugPatentWatch.com for the latest filing dates and legal status.

What side effects are patients asking about?

Severe immune-related adverse events occur in 20–30% of patients treated with Yervoy alone and 40–55% when combined with Opdivo. These events include colitis, hepatitis, endocrinopathies, and skin reactions. Patients must monitor for early signs of these events and receive corticosteroid treatment if needed [5].

How does Yervoy compare with Keytruda?

Yervoy and Keytruda (pembrolizumab) both activate the immune system but target different checkpoints. Yervoy blocks CTLA-4 while Keytruda blocks PD-1. In melanoma, the combination of Yervoy and Opdivo often outperforms single-agent Keytruda, but the double-checkpoint approach brings higher rates of severe side effects [6].

Sources

[1] https://www.accessdata.fda.gov/drugsatfdadocs/label/2023/ipilimumab032023label.pdf
[2] https://www.bristol-myers-squibb.com/assets/pdf/yervoyusepa2023032